Similar articles for PMID: 19223503

Year	Number of Results
1990	2
1992	1
1993	1
1994	1
1995	2
1996	2
1997	2
1998	1
1999	1
2001	5
2002	5
2003	4
2004	5
2005	11
2006	14
2007	12
2008	9
2009	26
2010	20
2011	19
2012	21
2013	21
2014	28
2015	35
2016	33
2017	20
2018	28
2019	26
2020	26
2021	19
2022	21
2023	9
2024	0

1

Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy.

Zhao MY, Auerbach A, D'Costa AM, Rapoport AP, Burger AM, Sausville EA, Stass SA, Jiang F, Sands AM, Aguilera N, Zhao XF. Zhao MY, et al. Clin Cancer Res. 2009 Mar 1;15(5):1708-20. doi: 10.1158/1078-0432.CCR-08-1543. Epub 2009 Feb 17. Clin Cancer Res. 2009. PMID: 19223503

2

Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma.

Zhao XF, Gartenhaus RB. Zhao XF, et al. Expert Opin Ther Targets. 2009 Sep;13(9):1085-93. doi: 10.1517/14728220903103833. Expert Opin Ther Targets. 2009. PMID: 19614561 Review.

3

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S. Petrich AM, et al. Clin Cancer Res. 2012 May 1;18(9):2534-44. doi: 10.1158/1078-0432.CCR-11-1407. Epub 2012 Feb 14. Clin Cancer Res. 2012. PMID: 22338016 Free PMC article.

4

Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab.

Wanner K, Hipp S, Oelsner M, Ringshausen I, Bogner C, Peschel C, Decker T. Wanner K, et al. Br J Haematol. 2006 Sep;134(5):475-84. doi: 10.1111/j.1365-2141.2006.06210.x. Br J Haematol. 2006. PMID: 16856892 Free article.

5

Amplified RPS6KB1 and CDC2 genes are potential biomarkers for aggressive HIV+/EBV+ diffuse large B-cell lymphomas.

Zhao XF, Zhao MY, Chai L, Kukuruga D, Tan M, Stass SA. Zhao XF, et al. Int J Clin Exp Pathol. 2013;6(2):148-54. Epub 2013 Jan 15. Int J Clin Exp Pathol. 2013. PMID: 23330000 Free PMC article.

6

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.

Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, Chen LY, Li JM. Xu ZZ, et al. Ann Hematol. 2013 Oct;92(10):1351-8. doi: 10.1007/s00277-013-1770-9. Epub 2013 May 2. Ann Hematol. 2013. PMID: 23636313

7

Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, Claret FX, Rassidakis GZ. Vega F, et al. Cancer Res. 2006 Jul 1;66(13):6589-97. doi: 10.1158/0008-5472.CAN-05-3018. Cancer Res. 2006. PMID: 16818631 Free PMC article.

8

MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.

Go H, Jang JY, Kim PJ, Kim YG, Nam SJ, Paik JH, Kim TM, Heo DS, Kim CW, Jeon YK. Go H, et al. Oncotarget. 2015 Jun 20;6(17):15035-49. doi: 10.18632/oncotarget.3729. Oncotarget. 2015. PMID: 25909227 Free PMC article.

9

FRAP-p70s6K signaling is required for pancreatic cancer cell proliferation.

Shah SA, Potter MW, Ricciardi R, Perugini RA, Callery MP. Shah SA, et al. J Surg Res. 2001 May 15;97(2):123-30. doi: 10.1006/jsre.2001.6145. J Surg Res. 2001. PMID: 11341787

10

Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.

Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, Kondo S. Takeuchi H, et al. Cancer Res. 2005 Apr 15;65(8):3336-46. doi: 10.1158/0008-5472.CAN-04-3640. Cancer Res. 2005. PMID: 15833867

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

384 results

Results by year